Article

Hilco Vision’s Las Vegas facility receives National Association of Boards of Pharmacy (NABP) Drug Distributor Accreditation

Author(s):

This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.

a photo of the welcome to las vegas sign with the skyline in the background. (Image Credit: AdobeStock/somchaij)

(Image Credit: AdobeStock/somchaij)

The NABP Drug Distributor Accreditation is a resource for industry and regulatory bodies that establish uniform safeguards meant to protect the public health. This distinction plays a pivotal role in preventing counterfeit drugs from entering the United States drug supply and protects the public from drugs that have been contaminated, diverted, or counterfeited. This accreditation process required Hilco Vision to demonstrate compliance to a comprehensive set of regulatory standards and best practices in safely distributing prescription drugs from manufacturers to pharmacies and other institutions.

“It is more important than ever to strive for the highest standards of compliance in pharmaceutical distribution. This accreditation for our Nevada facility demonstrates our commitment to continuous improvement in supply chain on behalf of our customers,” says Ross Brownlee, CEO of Hilco Vision in the company’s news release.

NABP Executive Director/Secretary Lemrey “Al” Carter, PharmD, MS, RPh shared how this accreditation of Hilco’s Las Vegas facility is key to public health. In the press release, he said, “NABP congratulates Hilco Vision on achieving this important recognition. By earning the Drug Distributor Accreditation, they demonstrate their commitment to preventing counterfeit drugs from entering the US drug supply, and they hold a pivotal role in protecting the public health.”

Reference:
Hilco Vision Earns NABP Drug Distributor Accreditation. Hilco Vision. July 10, 2023. Accessed July 11, 2023. https://news.hilcovision.com/2023/07/hilco-vision-earns-nabp-drug-distributor-accreditation/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.